 | |
| Clinical data | |
|---|---|
| Other names | 2-Furylethylamine; Furylethylamine; 2-Furan-2-yl-ethylamine; 2-Furanethanamine; 2-(2-Furyl)ethanamine; 2-(2-Aminoethyl)furan; 2-(Furan-2-yl)ethan-1-amine; Furfurylmethylamine |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.128.411 |
| Chemical and physical data | |
| Formula | C6H9NO |
| Molar mass | 111.144 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2-Furylethylamine (2-FEA orFEA) is adrug of thearylalkylamine family related to thesubstituted phenethylamines such asβ-phenethylamine (PEA) andamphetamine.[1] It is known to have similarpressor effects as amphetamine and strong constricting effects on theuterus in animals.[1][2][3] Thepsychoactive effects of FEA in humans are unknown.[1]
Derivatives of FEA includeα-Me-FEA (furylisopropylamine) andα,N-Me-FEA, among others.[1][2] α-Me-FEA was less several-foldpotent than amphetamine in animals and showed limited effects in humans.[2]Analogues of FEA, besides β-phenethylamine (PEA) and amphetamine (α-Me-PEA), includeTH-FEA,α-Me-TH-FEA,ThEA,thiopropamine (α-Me-ThEA),3-ThEA,2-(2-pyrrolyl)ethylamine (NEA), andα-Me-NEA, among others.[1][2] Some of them are known to be active.[1][2]
FEA was firstsynthesized by 1920.[1][3] FEA and analogues were studied byGordon Alles and colleagues, who discovered its pressor effects.[1][2] FEA is not acontrolled substance in theUnited States as of 2011.[1]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
